Company intelligence / Profile preview

Qinheli

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Qinheli is a China-based biotechnology company focused on the discovery and development of next-generation small molecule therapeutics, with a particular emphasis on molecular glue degraders. Founded in 2021 by industry veterans, the company leverages its proprietary platform to target "undruggable" proteins involved in cancer and autoimmune diseases. Qinheli's pipeline includes several programs in the pre-clinical and IND-enabling stages, targeting proteins such as GSPT1 and IKZF2. The company has secured significant backing from prominent investors like Qiming Venture Partners to advance its targeted protein degradation (TPD) portfolio.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeMolecular glue therapyProteolysis-targeting chimera therapy
Industry: Biotech

Beyond the preview

Go deeper on Qinheli.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qinheli.

Explore the full profile